In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis

In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis

Abstract Background Sustained drug delivery is a large unmet clinical need in glaucoma. Here, we incorporated a Myocardin-Related Transcription Factor/Serum Response Factor inhibitor, CCG-222740, into slow release large unilamellar vesicles derived from the liposomes DOTMA (1,2-di-O-octadecenyl-3-tr...

Full description

Bibliographic Details
Main Authors: Aristides D. Tagalakis, Shivam Madaan, Scott D. Larsen, Richard R. Neubig, Peng T. Khaw, Ian Rodrigues, Saurabh Goyal, Kin Sheng Lim, Cynthia Yu-Wai-Man
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Journal of Nanobiotechnology
Subjects:
Nanocarrier
Sustained release
Inhibitor
Glaucoma
Fibrosis
Online Access:http://link.springer.com/article/10.1186/s12951-018-0425-3

Internet

http://link.springer.com/article/10.1186/s12951-018-0425-3

Similar Items